nach oben

Erschienen in:

01.01.2011 | Review

Update in Addiction Medicine for the Generalist

verfasst von: Adam J. Gordon, MD, MPH, Hillary V. Kunins, MD, MPH, MS, Darius A. Rastegar, MD, Jeanette M. Tetrault, MD, Alexander Y. Walley, MD, MSc

Erschienen in: Journal of General Internal Medicine | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Excerpt

Generalist clinicians routinely care for patients who misuse or are dependent on alcohol, nicotine, and other drugs of abuse.1,2 These problems contribute to significant morbidity, health care utilization, cost, and preventable death.3,4 The aim of this update is to identify and examine recent advances in addiction medicine that have practice implications for generalist physicians and their patients. To accomplish this, we independently selected articles in the field of addiction medicine, summarized and critically appraised, and examined the articles in the context of their implications for generalist practice using methodology we used in prior updates.5,6 During an initial review, we identified articles through an electronic MedLine search (limited to human studies and in English) using search terms for alcohol, nicotine, and other drugs of abuse from January 2008 through January 2010. From the citations, the authors selected articles for more intensive review. After this initial review, we searched for other literature in web-based or journal resources (e.g., www.aodhealth.org, ACP Journal Club, table of contents of relevant journals). All authors then agreed collectively on the important articles regarding addiction medicine that have implications for practice for generalist clinicians. …

Robins LN, Helzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry. 1984;41(10):949–58.PubMed

Institute of Medicine. Improving the quality of healthcare for mental and substance-use conditions: The quality chasm series. Washington, DC: The National Academies Press; 2005.

Institute of Medicine. Crossing the quality chasm: A new health system for the 21st century. Washington, DC: The National Academies Press; 2001.

Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238–45.CrossRefPubMed

Gordon AJ, Sullivan LE, Alford DP, et al. Update in addiction medicine for the generalist. J Gen Intern Med. 2007;22(8):1190–4.CrossRefPubMed

Gordon AJ, Fiellin DA, Friedmann PD, et al. Update in addiction medicine for the primary care clinician. J Gen Intern Med. 2008;23(12):2112–6.CrossRefPubMed

Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85–92.PubMed

Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300(22):2613–20.CrossRefPubMed

Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 2009;104(6):993–9.CrossRefPubMed

10.

Paulozzi LJ, Logan JE, Hall AJ, McKinstry E, Kaplan JA, Crosby AE. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction. 2009;104(9):1541–8.CrossRefPubMed

11.

Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc Interval Screening in Methadone Treatment: the CSAT Consensus Guideline. Ann Intern Med. 2008.

12.

Gourevitch MN. First do no harm…Reduction? Ann Intern Med. 2009;150(6):417–8.PubMed

13.

McLellan AT, Turner BJ. Chronic noncancer pain management and opioid overdose: time to change prescribing practices. Ann Intern Med. 2010;152(2):123–4.PubMed

14.

Solberg LI, Maciosek MV, Edwards NM. Primary care intervention to reduce alcohol misuse ranking its health impact and cost effectiveness. Am J Prev Med. 2008;34(2):143–52.CrossRefPubMed

15.

D'Amico EJ, Paddock SM, Burnam A, Kung FY. Identification of and guidance for problem drinking by general medical providers: results from a national survey. Med Care. 2005;43(3):229–36.CrossRefPubMed

16.

Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. Primary care validation of a single-question alcohol screening test. J Gen Intern Med. 2009;24(7):783–8.CrossRefPubMed

17.

Friedmann PD, McCullough D, Chin MH, Saitz R. Screening and intervention for alcohol problems. A national survey of primary care physicians and psychiatrists. J Gen Intern Med. 2000;15(2):84–91.CrossRefPubMed

18.

Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption–II. Addiction. 1993;88(6):791–804.CrossRefPubMed

19.

Allen JP, Litten RZ, Fertig JB, Babor T. A review of research on the Alcohol Use Disorders Identification Test (AUDIT). Alcoholism: Clinical & Experimental Research. 1997;21(4):613–9.

20.

The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction. 2002;97(9):1183-94.

21.

Vinson DC, Kruse RL, Seale JP. Simplifying alcohol assessment: two questions to identify alcohol use disorders. Alcohol Clin Exp Res. 2007;31(8):1392–8.CrossRefPubMed

22.

Dawson DA, Grant BF, Stinson FS, Zhou Y. Effectiveness of the derived Alcohol Use Disorders Identification Test (AUDIT-C) in screening for alcohol use disorders and risk drinking in the US general population. Alcohol Clin Exp Res. 2005;29(5):844–54.CrossRefPubMed

23.

Gordon AJ, Maisto SA, McNeil M, et al. Three questions can detect hazardous drinkers. J Fam Pract. 2001;50(4):313–20.PubMed

24.

Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Arch Intern Med. 1998;158(16):1789–95.CrossRefPubMed

25.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.

26.

Cervantes EA, Miller WR, Tonigan JS. Comparison of Timeline Follow-Back and Averaging Methods for Quantifying Alcohol Consumption in Treatment Research. Assessment. 1994;1(1):23–30.CrossRefPubMed

27.

Maisto SA, Conigliaro JC, Gordon AJ, Mcginnis KA, Justice AC. An experimental study of the agreement of self-administration and telephone administration of the Timeline Followback interview. J Stud Alcohol Drugs. 2008;69(3):468–71.PubMed

28.

Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 2009;99(1–3):280–95.CrossRefPubMed

29.

Krupski A, Sears JM, Joesch JM et al. Impact of brief interventions and brief treatment on admissions to chemical dependency treatment. Drug Alcohol Depend. 2010.

30.

Babor TF, McRee BG, Kassebaum PA, Grimaldi PL, Ahmed K, Bray J. Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse. Subst Abus. 2007;28(3):7–30.CrossRefPubMed

31.

The impact of screening, brief intervention, and referral for treatment on emergency department patients' alcohol use. Ann Emerg Med. 2007;50(6):699-710, 710.

32.

Fleming MF, Barry KL, Manwell LB, Johnson K, London R. Brief physician advice for problem alcohol drinkers. A randomized controlled trial in community-based primary care practices. JAMA. 1997;277(13):1039–45.CrossRefPubMed

33.

Fleming MF, Mundt MP, French MT, Manwell LB, Stauffacher EA, Barry KL. Brief physician advice for problem drinkers: long-term efficacy and benefit-cost analysis. Alcohol Clin Exp Res. 2002;26(1):36–43.PubMed

34.

Otto C, Crackau B, Lohrmann I, et al. Brief intervention in general hospital for problematic prescription drug use: 12-month outcome. Drug Alcohol Depend. 2009;105(3):221–6.CrossRefPubMed

35.

Zahradnik A, Otto C, Crackau B, et al. Randomized controlled trial of a brief intervention for problematic prescription drug use in non-treatment-seeking patients. Addiction. 2009;104(1):109–17.CrossRefPubMed

36.

McQueen J, Howe TE, Allan L, Mains D. Brief interventions for heavy alcohol users admitted to general hospital wards. Cochrane Database Syst Rev. 2009;(3):CD005191.

37.

Guth S, Lindberg SA, Badger GJ, Thomas CS, Rose GL, Helzer JE. Brief intervention in alcohol-dependent versus nondependent individuals. J Stud Alcohol Drugs. 2008;69(2):243–50.PubMed

38.

Stewart SH, Latham PK, Miller PM, Randall P, Anton RF. Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction. 2008;103(10):1622–8.CrossRefPubMed

39.

Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–17.CrossRefPubMed

40.

Nordback I, Pelli H, Lappalainen-Lehto R, Jarvinen S, Raty S, Sand J. The recurrence of acute alcohol-associated pancreatitis can be reduced: a randomized controlled trial. Gastroenterology. 2009;136(3):848–55.CrossRefPubMed

41.

Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805.CrossRefPubMed

42.

Quinn VP, Hollis JF, Smith KS, et al. Effectiveness of the 5-As tobacco cessation treatments in nine HMOs. J Gen Intern Med. 2009;24(2):149–54.CrossRefPubMed

43.

Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2008;(3):CD006103.

44.

Kuehn BM. Studies linking smoking-cessation drug with suicide risk spark concerns. JAMA. 2009;301(10):1007–8.CrossRefPubMed

45.

Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf. 2009;32(6):499–507.CrossRefPubMed

46.

Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393–8.CrossRefPubMed

47.

Drug Addiction Treatment Act of 2000, 42 USC§3502a, Drug Addiction Treatment Act of 2000, (2000)

48.

Barry DT, Irwin KS, Jones ES et al. Integrating Buprenorphine Treatment into Office-based Practice: a Qualitative Study. J Gen Intern Med. 2008.

49.

Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009;37(4):426–30.CrossRefPubMed

50.

Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2004;(3):CD002207.

51.

Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict. 2008;17(2):116–20.CrossRefPubMed

52.

Parran TV, Adelman CA, Merkin B, et al. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010;106(1):56–60.CrossRefPubMed

53.

Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–58.CrossRefPubMed

54.

Gordon AJ, Trafton JA, Saxon AJ, et al. Implementation of buprenorphine in the Veterans Health Administration: Results of the first 3 years. Drug Alcohol Depend. 2007;90:292–6.CrossRefPubMed

55.

Gordon AJ, Liberto J, Granda S, Salmon-Cox S, Andree T, McNicholas L. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. Am J Addict. 2008;17(6):459–62.CrossRefPubMed

56.

Miller NS, Sheppard LM, Colenda CC, Magen J. Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Acad Med. 2001;76(5):410–8.CrossRefPubMed

Titel: Update in Addiction Medicine for the Generalist
verfasst von: Adam J. Gordon, MD, MPH
Hillary V. Kunins, MD, MPH, MS
Darius A. Rastegar, MD
Jeanette M. Tetrault, MD
Alexander Y. Walley, MD, MSc
Publikationsdatum: 01.01.2011
Verlag: Springer-Verlag
Erschienen in: Journal of General Internal Medicine / Ausgabe 1/2011
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-010-1461-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Auf Antibiotika verzichten? Was bei unkomplizierter Zystitis hilft

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO₂. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Assessing the Quality of Clinical Teachers

Deeper Problems in the Marketing of Drugs

The Effect of Medication Samples on Self-Reported Prescribing Practices: A Statewide, Cross-Sectional Survey

The Effect of Workload Reduction on the Quality of Residents’ Discharge Summaries

I Believe, Therefore I Do